Boston Scientific (NYSE:BSX) Upgraded to “Outperform” at Oppenheimer

Oppenheimer upgraded shares of Boston Scientific (NYSE:BSX) from a market perform rating to an outperform rating in a research report released on Monday morning, MarketBeat reports. The firm currently has $125.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $118.00.

Several other research firms have also weighed in on BSX. Morgan Stanley upped their price target on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Citigroup reissued a “buy” rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Raymond James Financial increased their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Finally, Robert W. Baird increased their target price on Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $117.79.

Boston Scientific Stock Down 2.6%

Shares of Boston Scientific stock opened at $105.32 on Monday. The stock’s fifty day moving average is $104.88 and its 200-day moving average is $102.24. The firm has a market capitalization of $156.06 billion, a PE ratio of 62.69, a price-to-earnings-growth ratio of 2.60 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors have recently bought and sold shares of the business. Investment Management Corp VA ADV acquired a new stake in Boston Scientific during the 4th quarter worth $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific in the fourth quarter valued at about $26,000. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at about $26,000. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at about $26,000. Finally, Y.D. More Investments Ltd bought a new stake in Boston Scientific in the first quarter valued at about $27,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.